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Abstract
Background: Gestational diabetes mellitus (GDM) is associated with perinatal health risks to both mother and
offspring, and represents a large economic burden. The DALI study is a multicenter randomized controlled trial,
undertaken to add to the knowledge base on the effectiveness of interventions for pregnant women at increased
risk for GDM. The purpose of this study was to evaluate the cost-effectiveness of the healthy eating and/or physical
activity promotion intervention compared to usual care among pregnant women at increased risk of GDM from a
societal perspective.
Methods: An economic evaluation was performed alongside a European multicenter-randomized controlled trial. A
total of 435 pregnant women at increased risk of GDM in primary and secondary care settings in nine European
countries, were recruited and randomly allocated to a healthy eating and physical activity promotion intervention
(HE + PA intervention), a healthy eating promotion intervention (HE intervention), or a physical activity promotion
intervention (PA intervention). Main outcome measures were gestational weight gain, fasting glucose, insulin
resistance (HOMA-IR), quality adjusted life years (QALYs), and societal costs.
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Results: Between-group total cost and effect differences were not significant, besides significantly less gestational
weight gain in the HE + PA group compared with the usual care group at 35–37 weeks (−2.3;95%CI:-3.7;-0.9). Cost-
effectiveness acceptability curves indicated that the HE + PA intervention was the preferred intervention strategy. At
35–37 weeks, it depends on the decision-makers’ willingness to pay per kilogram reduction in gestational weight
gain whether the HE + PA intervention is cost-effective for gestational weight gain, whereas it was not cost-
effective for fasting glucose and HOMA-IR. After delivery, the HE + PA intervention was cost-effective for QALYs,
which was predominantly caused by a large reduction in delivery-related costs.
Conclusions: Healthy eating and physical activity promotion was found to be the preferred strategy for limiting
gestational weight gain. As this intervention was cost-effective for QALYs after delivery, this study lends support for
broad implementation.
Trial registration: ISRCTN ISRCTN70595832. Registered 2 December 2011.
Keywords: Economic evaluation, Cost-effectiveness, Gestational diabetes, Lifestyle intervention, Pregnant women
Background
Glucose intolerance with its onset during pregnancy (i.e.
Gestation Diabetes Mellitus; GDM) is associated with
perinatal health risks to both mother and offspring, and
represents a large economic burden [1–4]. Women ex-
periencing GDM are also at increased risk for the future
development of type-2 diabetes, where prevention
through lifestyle change has been found to be cost-
effective among high risk individuals [5–8]. As many of
the pathophysiological processes underlying GDM are
similar to those of type-2 diabetes, such interventions
could also be useful for GDM prevention. However, to
avoid fetal harm, they should aim to limit gestational
weight gain, rather than reduce weight [9].
Evidence on the effectiveness of interventions aimed
at limiting gestational weight gain is mixed. A meta-
analysis found dietary counseling to significantly re-
duce GDM, whereas no effect on maternal fasting
glucose was found [10]. A more recent systematic re-
view of 13 randomized controlled trials did not find a
significant difference in the risk of developing GDM
between women receiving a physical activity and
healthy eating promotion intervention compared with
those receiving no intervention [11]. However, as the
methodological quality of the existing evidence is low
to moderate, more high quality randomized controlled
trials are needed to investigate the effectiveness of
interventions that are aimed at pregnant women at
increased risk of GDM.
To add to the knowledge base on the effectiveness of
interventions for pregnant women at increased risk for
GDM, the DALI study was undertaken. The DALI study
is a multicenter randomized controlled trial conducted
in nine European countries [12]. The study found a
healthy eating and physical activity promotion interven-
tion to reduce gestational weight gain, but not GDM risk
[13]. There is evidence, however, that limiting gestational
weight gain could be beneficial in its own right through
improved obstetric outcomes [14, 15].
Decisions about investments in health programs are
not only guided by their effectiveness, but also by their
additional costs in relation to these effects (i.e. cost-
effectiveness) [16]. The latter is evaluated through an
economic evaluation. In times of increasing healthcare
costs and tight budgets, such studies provide important
information for decision-makers to weigh alternative
courses of action and to decide which programs to im-
plement and/or reimburse [17].
The present study aimed to evaluate the cost-
effectiveness of a healthy eating and/or physical activity
promotion intervention compared to usual care among
pregnant women at increased risk of GDM from a soci-
etal perspective.
Methods
Design and participants
The DALI study is a multicenter randomized controlled
trial with a factorial study design that was conducted in
nine European countries (2012–2015) [12, 13]. Pregnant
women attending a participating antenatal clinic or
hospital were asked to participate in the study. The par-
ticipating centers were located in the United Kingdom,
Ireland, Austria, Poland, Italy (Padua, Pisa), Spain,
Denmark (Odense, Copenhagen), Belgium, and the
Netherlands. Pregnant women with a pre-pregnancy
body mass index (BMI) of ≥29 kg/m2 were eligible for
inclusion [12]. Further inclusion criteria were ≤19 +
6 days of gestation, having a singleton pregnancy, and
being aged ≥18 years. Women were excluded if they:
were diagnosed with GDM by oral glucose tolerance test-
ing [18]; had pre-existing diabetes; were not able to walk
≥100 m safely; required complex diets; had chronic med-
ical conditions; had a psychiatric disorder; were not fluent
in the major language of the country of recruitment or
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were unable to have a conversation with the lifestyle coach
in another language for which translated intervention ma-
terials were available. After the provision of informed con-
sent, baseline assessment occurred <20 weeks of gestation
and was immediately followed by randomization [12]. The
CONSORT (Consolidated Standards Of Reporting Trials)
checklist is available as Additional file 1.
Randomization
Participants were randomly allocated to one of the four
arms of the DALI study, comparing 1) a healthy eating
and physical activity promotion intervention (HE + PA
intervention), 2) a healthy eating promotion intervention
(HE intervention), and 3) a physical activity promotion
intervention (PA intervention) with 4) usual care (Fig. 1).
Randomization was performed using a computerized
random number generator and was pre-stratified for
intervention center and the trial’s 2 × 2 design. The trial
coordinator prepared and distributed sealed opaque en-
velopes containing the intervention arm to which the
participants were allocated. Prior to the start of the
intervention, the allocation outcome was communicated
to the participants by the lifestyle coach.
DALI intervention
The DALI lifestyle coaching intervention was targeted at
HE + PA, HE, or PA. A detailed description of the inter-
vention conditions is reported elsewhere [12] .In brief, life-
style coaching was offered during five face-to-face sessions
of 30–45 min and four optional telephone calls of
≤20 min that occurred between the face-to-face sessions.
Participants were assigned to one lifestyle coach [19, 20].
Face-to-face sessions occurred at the participants’ home
or at the nearest hospital, midwife practice, or general
practice. To optimize intervention uptake, timing and in-
tervals between face-to-face and telephone contacts were
tailored to the participants’ preferences. It was stressed,
however, that at least 4 face-to-face coaching sessions
should occur before the second measurement and that the
intervention should be finished before 35 weeks of gesta-
tion. Lifestyle coaches used a PDA (or, where unavailable,
a paper version), providing a framework for the face-to-
face and telephone sessions and guidance for intervention
delivery. Detailed description of the DALI intervention is
reported in the TIDieR (Template for Intervention
Description and Replication) checklist in Additional file 2.
Usual care
During pregnancy, usual care group participants re-
ceived care as usual by their midwife or obstetrician and
did not receive any of the lifestyle interventions.
Baseline characteristics
Potential confounders were assessed at baseline by question-
naire, including age (years), ethnicity (European descent:yes/
no), multiparous pregnancy (yes/no), education level (higher
education:yes/no), history of GDM (yes/no), height (cm),
pre-pregnancy weight and weight at study entry (kilo-
gram), BMI (kg/m2), and gestation at study entry (weeks).
Study outcomes
Clinical outcomes included gestational weight gain, fast-
ing glucose, insulin resistance (HOMA-IR), and health-
related quality of life [12, 13].
Fig. 1 CONSORT diagram. CONSORT diagram of recruitment, randomization and drop out of the DALI lifestyle trial
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Weight was measured at baseline (<20 weeks), 24–
28 weeks, and 35–37 weeks. Gestational weight gain was
defined as the participants’ weight change from baseline
to 35–37 weeks. Fasting glucose and HOMA-IR were
measured at baseline, 24–28 weeks, and 35–37 weeks as
well. Anthropometric and laboratory measurements
followed a standardized methodology as described
elsewhere [12].
Health-related quality of life was assessed at baseline
(<20 weeks), 24–28 weeks, and at 35–37 weeks using
the EQ-5D-3 L [21]. Since many costs that are associ-
ated with the interventions under study are likely related
to the delivery of babies, costs were measured until after
delivery (i.e. 24–28 h after delivery). Therefore, health-
related quality of life was assessed at 24–48 h after deliv-
ery as well. Utilities were estimated using the European
tariff [22]. Quality adjusted life years (QALYs) were
calculated by multiplying the utilities by the amount of
time spent in a health state. For this purpose, transitions
between EQ-5D-3 L health states were linearly
interpolated.
Cost measures
Resource use data were collected by questionnaire at
24–28 weeks, 35–37 weeks, and 24–48 after delivery.
Additional resource use data concerning the delivery
and other delivery-related in-hospital services were
collected from hospital records. Costs were measured
from a societal perspective and included intervention,
medical, absenteeism, and travel costs. All costs were
expressed in Euros 2012 [23]. Due to a limited availabil-
ity of unit costs reflecting the “true cost” of a good or
service for most of the participating countries, unit costs
were based on Dutch costing data. To correct for the
fact that the relative prices of factors differ across
countries, unit costs were adjusted per country using
purchasing power parities [24, 25]. An overview of the
unit costs per country can be found in Additional file 3.
Intervention costs included all costs related to the
development, implementation, and execution of the in-
terventions, and were estimated using a bottom-up
micro-costing approach. The latter means that interven-
tion costs were estimated by collecting detailed informa-
tion regarding the quantities of resources consumed
while implementing and executing the interventions as
well as their respective unit prices. Frequency and dur-
ation of face-to-face and telephone sessions were based
on pilot study data [13]. Time investments of interven-
tion providers were valued using their gross hourly salar-
ies. Material and website hosting costs were estimated
using invoices. Medical costs included costs related to
the use of primary healthcare (i.e. care by a GP, a
midwife, a dietician, and a diabetes counselor), second-
ary healthcare (i.e. outpatient hospital visits, maternal
hospitalization, neonatal hospitalization, delivery, and in-
hospital ultrasounds, fetal non-stress tests, and blood
tests) and medication. Primary and secondary healthcare
use were valued using Dutch standard costs [26]. If un-
available, prices according to professional organizations,
hospital records, or a previously published economic
evaluation were used [27]. Medication use was valued
using prices of the “Royal Dutch Society of Pharmacy”
[28]. Absenteeism costs were estimated according to the
human capital approach, using the estimated price of
productivity losses per sickness absence day based on 5-
year age categories [26]. Unit costs for valuing travel
costs were derived from the “Dutch Manual of costing”
and varied by mode of transportation [26].
Statistical analysis
Analyses were performed according to the intention-to-
treat principle. Missing data were replaced using multiple
imputation, stratified by treatment group. The imputation
model included variables related to the “missingness” of
data or the outcome measure, and variables that differed
at baseline between groups [29]. Using Predictive Mean
Matching, 20 complete data sets were created to keep the
loss-of-efficiency below 5% [29]. Datasets were analyzed
separately as specified below. Pooled estimates were calcu-
lated using Rubin’s rules [30].
Effects on gestational weight gain, fasting glucose,
and HOMA-IR at 35–37 weeks and the effect on
QALYs gained from baseline till after delivery were
analyzed using multilevel analyses, adjusted for base-
line values and follow-up duration (in weeks). Two
levels were identified: study centers (n = 11) and par-
ticipants (n = 435). Total and disaggregated cost differ-
ences were also estimated using linear multilevel
analyses, with the same two-level structure and ad-
justed for follow-up duration as well. 95%CIs around
cost differences were estimated using bias-corrected
(BC) bootstrapping, with 5000 replications (stratified
by study center). Incremental cost-effectiveness ratios
(ICERs) were calculated by dividing the total cost
differences by those in effects. For this purpose, the
difference in total costs at 35–37 weeks was divided
by the difference in gestational weight gain, fasting
glucose, and HOMA-IR at 35–37 weeks and the difference
in total costs after delivery by the difference in QALYs
gained after delivery. Bootstrapped incremental cost-effect
pairs were plotted on cost-effectiveness planes. Cost-
effectiveness acceptability curves (CEACs) were con-
structed, showing the interventions’ probability of being
cost-effective compared with usual care at various
willingness-to-pay (WTP) values.
Analyses were performed using Stata 12.0. Statistical
significance was set at p < 0.05.
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Sensitivity analyses
Four sensitivity analyses (SAs) were performed. In SA1,
national tariffs were used for estimating QALYs [31–35],
instead of the European tariff. In SA2, United Kingdom
(UK) unit costs data were used for valuing resource use,
instead of Dutch ones. UK unit costs were used in SA2,
as previous research indicates that a large share of
European economic evaluations is carried out in the UK,
and thus relies on UK costing data as well [36]. UK unit
costs were derived from previously published studies,
international databases, hospital records, and published
UK pricing lists [37–40]. In SA3, analyses were per-
formed from the healthcare perspective. In SA4, solely
participants with complete cost and effect data were
included.
Results
Participants
Of the participants, 107 were randomized to the HE + PA
group, 114 to the HE group, 110 to the PA group, and 104
to the usual care group (Fig. 1). At baseline, demographic
and clinical characteristics were comparable across group
(Table 1). After 35–37 weeks, complete data were available
for 75 participants (68%) in the HE + PA group, 80 partici-
pants (70%) in the HE group, 73 participants (68%) in the
PA group, and 72 participants (69%) in the usual care
group. After delivery, complete data were available for 48
participants (44%) in the HE + PA group, 51 participants
(45%) in the HE group, 46 participants (43%) in the PA
group, and 41 participants (39%) in the usual care group.
Resource use data concerning the delivery of babies and
other delivery-related in-hospital services were complete
for the majority of participants (n = 359; 83%). Relevant
differences were found between participants with
complete and incomplete data in terms of the country
they lived in, and their ethnicity, pre-pregnancy weight,
and marital status (Table 1).
Effectiveness
After 35–37 weeks, gestational weight gain (in kilo-
grams) was significantly lower in the HE + PA group
compared with the usual care group (−2.3;95%CI:-3.7 to
−0.9). Gestational weight gain was also lower in the HE
group compared with the usual care group, but this dif-
ference was not significant. There was no significant
beneficial effect on fasting glucose, HOMA-IR, and
QALYs (Table 2).
Costs
Average intervention costs per participant ranged from
€426 (SEM = 8) in the PA group to €436 (SEM = 7) in
the HE + PA group. Table 3 provides an overview of all
total and disaggregate cost differences. At 35–37 weeks,
no significant differences in total societal costs were
found, but primary healthcare costs were significantly
lower in the HE + PA group compared with the usual
care group (−39;95%CI:-75 to −3). After delivery, total
societal costs were lower in the HE + PA group and the
PA group than in the usual care group and higher in the
HE group than in the usual care group, but these
between-group differences were not significant. Costs re-
lated to the delivery of the babies were the biggest con-
tributor to the total cost differences (Table 3).
Cost-effectiveness: Societal perspective
For gestational weight gain, ICERs indicated that the
HE + PA intervention and the HE intervention were on
average more costly and more effective than usual care,
while the PA intervention was on average more costly
and less effective than usual care (Table 2). Cost-
effectiveness acceptability curves indicated that if
decision-makers are not willing to pay anything per
kilogram decrease in gestational weight gain (i.e.
willingness-to-pay [WTP] = €0/kg), the likelihood of the
intervention being cost-effectiveness compared to usual
care was low for all interventions (i.e. a probability
≤0.27). At all WTP values, the HE + PA intervention had
the highest likelihood of being cost-effective in compari-
son with usual care. Given a WTP value of €600/kg and
€750/kg, for example, this intervention was 90% and
95% more likely to be cost-effective than usual care,
while the likelihood of the HE intervention or the PA
intervention being more cost-effective than usual care
was much lower (Fig. 2a).
For fasting glucose, ICERs indicated that the HE + PA
intervention and the PA intervention were on average
more costly and more effective than usual care, while the
HE intervention was on average more costly and less ef-
fective than usual care (Table 2). The likelihood of the
interventions’ being cost-effective compared with usual
care was low if decision-makers are not willing to pay
anything per mmol/l decrease in fasting glucose (i.e. a
probability ≤0.27). At higher WTP values, the HE + PA
and PA intervention’s likelihood of being cost-effective
in comparison with usual care gradually increased, while
that of the HE intervention gradually decreased. The
HE + PA intervention reached the highest likelihood of
being cost-effective compared with usual care (i.e. a 0.72
probability at a WTP of €600,000/mmol/l)(Fig. 2b).
For HOMA-IR, ICERs indicated that all interventions
were on average more costly and more effective than usual
care (Table 2). Again, the likelihood of the interventions’
being cost-effective compared with usual care was low if
decision-makers are not willing to pay anything per unit
increase on the HOMA-IR (i.e. a probability ≤0.27). At
higher WTP values, all of the interventions’ likelihood of
being cost-effective compared with usual care increased,
with the HE intervention reaching the highest likelihood
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of being cost-effective compared with usual care (i.e. a
0.93 probability at a WTP of €100,000/unit)(Fig. 2c).
For QALYs, ICERs indicated that the HE + PA inter-
vention was on average less costly and more effective than
usual care, the HE intervention was on average more
costly and less effective than usual care, and the PA inter-
vention was on average less costly and less effective than
usual care (Table 2). If decision-makers are not willing
to pay anything per QALY gained, the HE + PA interven-
tion and the PA intervention had a relatively high likeli-
hood of being cost-effective compared with usual care
(i.e. 0.91 for the HE + PA intervention and 0.82 for the
PA intervention), while that of the HE intervention was
low (i.e. 0.32). At all WTP values, the HE + PA interven-
tion had the highest likelihood of being cost-effective in
comparison with usual care. Given a WTP value of
€10,000/QALY and €80,000/QALY, for example, this
intervention was 93% and 98% more likely to be cost-
effective than usual care (Fig. 2d).
Sensitivity analyses
Sensitivity analyses indicated that the overall conclusions
of the current study would not change when using na-
tional QALY tariffs instead of European ones (SA1) and
UK unit cost data instead of Dutch unit cost data (SA2).
However, when the healthcare perspective was applied
instead of the societal perspective (SA3), total costs until
after delivery were significantly lower in the PA group
than in the usual care group, whereas this difference was
not significant in the main analysis. As a consequence,
the PA intervention had the highest likelihood of being
cost-effective compared with usual care if decision-
makers are not willing to pay anything per QALY gained,
whereas in the main analysis this was the case for the
HE + PA intervention. In accordance with the results of
the main analysis, however, the HE + PA intervention
had the highest likelihood of being cost-effective com-
pared with usual care at WTP values of €35,000/QALY
or more. When only participants with complete data
were included in the analysis instead of all participants
(SA4), the HE + PA intervention and PA intervention
had higher total costs compared with usual care after de-
livery, whereas they were lower in the main analysis. In
both analyses, however, these differences in costs were
not significant. The results of the sensitivity analyses can
be found in Additional file 4.
Discussion
Results of this study showed that a HE + PA intervention
had a higher likelihood of being cost-effective compared
Table 2 Cost-effectiveness analysis results (main analysis – Societal perspective)
HE + PA
Outcome measure Sample size ΔC (95%CI) ΔE (95%CI) ICER Distribution CE-plane (%)
Intervention Control € Points €/point NE SE SW NW
Gestational weight gain 107 104 380 (−811 to 1510) −2.3 (−3.7 to −0.9) −165 73.6 26.4 0.0 0.0
Fasting glucose 107 104 380 (−811 to 1510) 0.0 (−0.2 to 0.1) −9198 52.9 20.2 6.3 20.7
HOMA-IR 107 104 380 (−811 to 1510) 0.0 (−0.1 to 0.2) 8971 47.4 16.2 10.1 26.2
QALYs 107 104 −1627 (−4000 to 556) 0.02 (0.00 to 0.04) −91,254 7.8 88.8 3.0 0.4
HE
Outcome measure Sample size ΔC (95%CI) ΔE (95%CI) ICER Distribution CE-plane (%)
Intervention Control € Points €/point NE SE SW NW
Gestational weight gain 114 104 648 (−482 to 1759) −0.6 (−2.4 to 1.2) −1058 66.1 9.8 3.5 20.5
Fasting glucose 114 104 648 (−482 to 1759) 0.1 (0.0 to 0.3) 5247 2.7 0.7 12.6 83.9
HOMA-IR 114 104 648 (−482 to 1759) 0.2 (0.0 to 0.3) 4302 80.5 12.2 1.2 6.2
QALYs 114 104 653 (−1997 to 3343) 0.00 (−0.02 to 0.02) −241,959 24.9 12.9 18.7 43.6
PA
Outcome measure Sample size ΔC (95%CI) ΔE (95%CI) ICER Distribution CE-plane (%)
Intervention Control € Points €/point NE SE SW NW
Gestational weight gain 110 104 710 (−486 to 1875) 0.2 (−1.4 to 1.7) 4810 34.4 7.6 7.1 50.9
Fasting glucose 110 104 710 (−486 to 1875) 0.0 (−0.1 to 0.1) −74,480 48.8 8.9 5.8 36.6
HOMA-IR 110 104 710 (−486 to 1875) 0.1 (−0.1 to 0.3) 11,292 61.7 10.6 4.1 22.7
QALYs 110 104 −1155 (−3473 to 1142) 0.00 (−0.03 to 0.01) 146,179 2.9 16.3 65.9 14.8
Abbreviations: C Costs, E Effects, ICER Incremental Cost-Effectiveness Ratio, CE-plane Cost-Effectiveness plane, NE Northeast-Quadrant, SE Southeast-Quadrant, NW
Northwest-Quadrant, ZW Southwest-Quadrant
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with usual care among women at increased risk of GDM
than a HE only or PA only intervention. At 35–37 weeks,
the HE + PA intervention was significantly more effective
than usual care in preventing gestational weight gain,
whereas the HE and PA interventions were not. There
was no significant beneficial effect on fasting glucose,
HOMA-IR, and QALYs. At 35–37 weeks, the HE + PA
intervention’s cost-effectiveness for gestational weight
gain depends on the decision-makers’ willingness to pay
per kilogram reduction in gestational weight gain,
whereas the intervention does not seem to be cost-
effective for fasting glucose and HOMA-IR. The latter is
due to the fact that the maximum probability of cost-
effectiveness was relatively low for fasting glucose (i.e.
0.70) and relatively high probabilities of cost-effectiveness
(i.e. >0.90) are only reached for HOMA-IR of decision-
makers are willing to pay large amounts of money per unit
of effect gained (i.e. €25,000/unit). After the delivery of
babies, the HE + PA intervention was cost-effective com-
pared with usual care for QALYs. To illustrate, at the
lower bounds of the Dutch and UK WTP-threshold for
QALYs (i.e. €10,000 and €24,400/QALY gained, respect-
ively), the probability of the HE + PA intervention being
cost-effective compared with usual care was ≥0.93.
Except for the complete-case analysis, results were
supported by the sensitivity analyses. The difference in
results between the main analysis and the complete-
case analysis is likely due to selective drop-out. That is,
differences were found between participants with
complete and incomplete data, making the results of
the imputed analysis more valid [41].
Comparison with the literature
Only a few studies have evaluated the cost-effectiveness
of lifestyle interventions for pregnant women at in-
creased risk of GDM. Oostdam et al., for example, found
a physical activity promotion intervention for pregnant
women at increased risk of GDM not to be cost-effective
compared with usual care for fasting glucose, insulin
sensitivity, birth weight, and QALYs [42]. Although the
results of the current study were slightly more positive,
both studies did not show significant differences in
a c
b d
Fig. 2 Cost-effectiveness acceptability curves. Cost-effectiveness acceptability curves showing the probabilities of the intervention’s being cost-
effective in comparison with usual care for gestational weight gain (a), fasting glucose (b), and HOMA-IR (c), and QALYs (d)
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societal costs and effects between a physical activity pro-
motion intervention and usual care [42]. Kolu et al. did
find a significant effect on birth weight, but did not find
that a healthy eating and physical activity promotion
intervention for women at increased risk of GDM was
cost-effective compared with usual care for birth weight,
QALYs, and perceived health. Kolu et al., however,
included women with a BMI ≥ 25 kg/m2 instead of
≥29 kg/m2, which might explain why their healthy eating
and physical activity intervention was not cost-effective
in comparison with usual care for QALYs, whereas the
present one was. Dodd et al. found a healthy eating and
physical activity promotion intervention for pregnant
women at increased risk of GDM not to be associated
with significant cost savings, but with a high probability
of cost-effectiveness for having an infant birth weight
below 4 kg [43]. The latter intervention, however, did
not have a significant impact on gestational weight gain.
Recently, Poston et al. (2017) performed an economic
evaluation in which they compared a physical activity
and nutrition intervention for pregnant women at risk of
GDM with usual care. From the NHS perspective, they
found the intervention not to be cost-effective (i.e. at a
WTP of £30,000/QALY its probability of cost-effectiveness
was 0.01). This is in contrast with the present findings and
might be explained by the fact that women were only
followed up until 36 weeks of gestation, instead of until
after delivery [44].
Strengths and limitations
This study had several strengths, including its European
multicenter randomized controlled trial design, its prag-
matic trial design with a usual care control condition, its
use of objectively measured clinical outcomes, its use of
hospital records for collecting resource use data concern-
ing the delivery of babies and other delivery-related in-
hospital services (i.e. the biggest cost driver), as well as its
use of state-of-the-art statistical methods, such as multiple
imputation, bootstrapping, and multilevel analyses.
Several limitations are noteworthy as well. First, some
resource use data were collected using self-report of par-
ticipants, which may have caused “social desirability”
and/or “recall bias”. Second, due to a limited availability
of unit costs reflecting “true costs” for most of the
participating countries we were not able to use multi-
country unit cost data. To deal with this limitation, unit
costs were based on Dutch costing data and were ad-
justed per country using purchasing power parities [45].
We do not expect this limitation to have greatly influ-
enced our results, as the results were similar when using
UK unit costs. Nonetheless, as the use of multi-country
cost data is preferred in economic evaluations [46], the
development of more country-specific costing manuals,
including readily available unit costs, is encouraged.
Third, a relatively large number of participants had some
missing data. To deal with this limitation, missing data
were multiply imputed, which is generally acknowledged
as a more valid strategy for dealing with missing cost-
effectiveness data than naïve methods, such as mean
imputation [41].
Implications for practice
The results of the present study indicate that after an
initial investment in setting up the lifestyle coaching
intervention and enrollment infrastructure, the HE + PA
intervention was cost-effective compared with usual care
for QALYs, which was mostly due to large reductions in
costs related to the delivery of babies. In addition to
being cost-effective for QALYs, this intervention also
limited gestational weight gain, which is relevant for
weight development of the women postpartum. As such,
this study lends support for implementing a healthy eat-
ing and physical activity promotion intervention among
pregnant women at increased risk of GDM broadly.
Conclusion
A HE+ PA intervention was found to have a higher
likelihood of being cost-effective compared with usual care
among women at increased risk of GDM than a HE only
or PA only intervention. After 35–37 weeks, the HE + PA
intervention’s cost-effectiveness for gestational weight gain
depends on the decision-makers’ willingness to pay per
kilogram reduction in gestational weight gain, whereas it
was not cost-effective for fasting glucose and HOMA-IR.
After the delivery of babies, the HE + PA intervention was
cost-effective for QALYs, lending support for a broad im-
plementation of a healthy eating and physical activity inter-
vention among pregnant women at increased risk of GDM.
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